Ixazomib Rollover Study

NCT02924272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Lymphoma
Amyloidosis

Interventions

DRUG: Ixazomib

Sponsor

Takeda

Collaborators

[object Object]